Stan rekrutacji pochodzi z rejestrów badań i może się zmienić szybciej, niż zaktualizuje go sponsor. Nasz doradca sprawdzi aktualny stan w wybranym ośrodku. Nie publikujemy nazwisk lekarzy ani ich danych kontaktowych.
Cel badania
Opis z rejestru (w języku angielskim):
The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System).
Leczenie w badaniu
Lek / interwencja
Rola
Postać, podanie
DUO Transcatheter Tricuspid Coaptation Valve System
Wyrób medyczny
Kryteria udziału
Kryteria w języku angielskim, tak jak w rejestrze.
Kryteria włączenia kto może wziąć udział (6)
Presence of severe or greater tricuspid regurgitation as determined by the Echo Core Lab.
Patient is symptomatic despite medical therapy.
The local Site Heart Team determines the Patient is appropriate for transcatheter valve intervention.
The Patient's anatomy is suitable in the judgment of the Patient Selection Committee.
Age ≥18 years
The Patient has been informed of the nature of the study and agrees to its provisions and has provided written Informed Consent.
Kryteria wyłączenia kto nie może wziąć udziału (31)
Patient is currently participating in another clinical investigation that could affect the outcome of this trial.
Any previous tricuspid valve intervention that would interfere with the placement of the investigational device.
Moderate or greater tricuspid valve stenosis.
Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation
Pacemaker or implantable cardioverter-defibrillator (ICD) leads that would prevent appropriate placement of the investigational device.
Need for concomitant surgical or interventional procedure, known at the time of screening (e.g., CABG, Atrial Septal Defect (ASD) repair).
Ejection Fraction (EF) <25%
Echocardiographic evidence of unstable intracardiac mass, thrombus or vegetation
Patient has Systolic Pulmonary Pressure (sPAP) >60 mm Hg
Severe hemodynamic instability: cardiogenic shock or the need for inotropic support or Intra-Aortic Balloon Pump (IABP) or other percutaneous ventricular assist devices
Severe respiratory instability with continuous use of home oxygen
Severe right ventricular dysfunction
Untreated clinically significant coronary or carotid artery disease requiring revascularization surgical or interventional PCI.
Stroke or transient ischemic event within 90 days prior to the index procedure
Acute myocardial infarction within 30 days before the index procedure
Renal insufficiency (eGFR <25 ml/min) or currently on chronic dialysis
Active endocarditis within 6 months of the index procedure
Pulmonary embolism or deep vein thrombosis within the last 6 months
Any surgical, interventional, or transcatheter procedure within 30 days prior to the index procedure
Hypertrophic cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis
Life expectancy <1 year
Active infections requiring current antibiotic therapy
Known severe liver disease
Is on the waiting list for a transplant or has had a prior heart or lung transplant
Known active peptic ulcer or active GI bleed
Unable to take anticoagulant therapy
Any known major coagulation abnormalities, thrombocytopenia, platelets < 50,000/ml or severe anemia Hb <8 g/dl
Known patient is actively abusing drugs
Any known sensitivities or allergies to contrast (that cannot be adequately premedicated) and/or the device materials, including nickel and titanium
Patients who are pregnant or intend to become pregnant
Any condition making it unlikely the Patient will be able to complete all protocol procedures (including compliance with optimal medical therapy and immobility that would prevent completion of 6MWT), follow-up visits, or impact the scientific soundness of the clinical investigation result
To główne kryteria z rejestru. Pełną listę i ostateczną decyzję o udziale ustala lekarz prowadzący badanie.
Zapytaj o udział w tym badaniu
Zadzwoń, a nasz doradca ds. badań sprawdzi z Tobą wstępnie kryteria i pomoże skontaktować się z ośrodkiem. Kwalifikację zawsze przeprowadza lekarz w ośrodku. Udział w badaniu jest bezpłatny i dobrowolny.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 11 listopada 2026.